Clinical trials
Vaccination clinical trials
Below are recruiting vaccination clinical trials, each written for real people, not researchers. We’re tracking 600 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06805656RecruitingPhase 2
Trial to reduce HIV reservoirs aiming for treatment-free remission
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
São Paulo, São PauloAges 18–65 - NCT06414057Recruiting
HPV study for women at higher risk in Scotland
This study looks at ways to improve cervical cancer prevention for women in Scotland who face extra challenges, such as addiction, homelessness, prison, or sex work. It includes a vaccination and screening part, plus an interview to hear your views.
EdinburghAges 25–45 - NCT05213000Recruiting
Exercise program study to boost vaccine immune response
This study looks at whether regular light-to-moderate exercise around the time of getting an mRNA COVID-19 vaccine can improve your immune response. It may help researchers understand how stress and exercise affect how well vaccines work.
Ames, IowaAges 18–64 - NCT06463119Recruiting
Vaccine response registry for immune-weakened patients
This study creates a registry to track how people with weakened immune systems respond to vaccines. It helps doctors better understand which vaccines work best for patients like you.
GenevaAges Any age - NCT06253234RecruitingPhase 1
DC vaccine for recurrent high-grade gliomas
This trial tests a vaccine made from your own immune cells (dendritic cells) to see if it can help control recurrent or progressive high-grade gliomas. It is for people whose brain tumor has returned after standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT05937295RecruitingPhase 1
Peptide vaccine plus immunotherapy for a specific cancer gene fusion
This Phase 1 study tests a custom vaccine made to match a specific cancer genetic change (DNAJB1-PRKACA fusion). It’s combined with an approved immunotherapy (immune checkpoint inhibitor) to help your immune system recognize and fight the cancer. You may be considered if your cancer is advanced or has spread and you meet several blood/organ and health requirements.
Tübingen, Baden-WürtembergAges 18 years+ - NCT05749627Recruiting
Vaccine for advanced cancers using your tumor’s targets
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
Nanchang, JiangxiAges 18–70 - NCT05775718RecruitingPhase 2
Shingrix shot after bone marrow transplant to prevent shingles
This Phase 2 study tests whether an additional Shingrix (RZV) vaccine dose helps prevent shingles in people who previously had an allogeneic bone marrow or stem cell transplant. It focuses on people who are at least a year out from their first two Shingrix doses.
Aurora, ColoradoAges 18–79 - NCT05365048Recruiting
Promoting HPV vaccine visits in kids ages 9–12
This study looks at whether getting a provider recommendation helps more parents bring children ages 9–12 in for HPV vaccination. It may help increase vaccination uptake in pediatric clinics.
Pasadena, CaliforniaAges 21–70 - NCT04611022Recruiting
Help increase HPV vaccine completion in Denver families
This study tests an educational program to help people in Denver who have not yet started the HPV vaccine (or haven’t finished it) complete the vaccine series. It may help families understand the vaccine and follow through with completing the recommended doses.
Denver, ColoradoAges 18 years+ - NCT04299724RecruitingPhase 1
COVID-19 Vaccine Safety and Immune Response Study
This early-stage trial tests a new COVID-19 vaccine designed to teach your immune system to fight the virus. It is for people who have just tested positive for COVID-19 and are otherwise healthy.
Shenzhen, GuangdongAges 6 months–80 years - NCT06497010RecruitingEarly Phase 1
Personalized mRNA cancer vaccine for advanced solid tumors
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
Guiyang, China/GuizhouAges 18–75 - NCT02358187RecruitingPhase 2
Vaccine for children and teens with low-grade brain tumors
This trial tests a peptide vaccine plus a medication called poly-ICLC for people with certain low-grade gliomas that cannot be fully removed. The goal is to help the immune system recognize and attack the tumor.
Pittsburgh, PennsylvaniaAges 1–21 - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Birmingham, AlabamaAges 18 years+ - NCT07111078RecruitingPhase 1
New Flu Vaccine (Stem) with or without Booster
This trial tests a new type of flu vaccine that targets a part of the virus that doesn't change much (the stem). It is given with or without a special booster, and researchers want to see if it provides broader protection against different flu strains.
Bethesda, MarylandAges 18–50 - NCT06928922RecruitingEarly Phase 1
Inhaled mRNA vaccine for advanced lung cancer and lung metastases
This trial tests an inhaled dry powder vaccine that uses mRNA to help your immune system target cancer cells in the lungs. It is for people with advanced lung cancer or solid tumors that have spread to the lungs, who have already tried standard treatments.
BeijingAges Up to 99 years - NCT06754605RecruitingPhase 1/Phase 2
Testing a new RSV vaccine for safety and immune response
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
Langfang, HebeiAges 18–120 - NCT07407569RecruitingPhase 2
HPV vaccine study for women with HPV16
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
Antwerp, WilrijkAges 18–45 - NCT07280858RecruitingPhase 1/Phase 2
Testing a new sarbecovirus vaccine in healthy adults
This study tests a new vaccine called GBP511, designed to protect against several types of sarbecoviruses (including COVID-19). It is for healthy adults who have already received a primary COVID-19 vaccine series plus at least one booster, at least 24 weeks before joining.
Sydney, Kent StreetAges 18 years+ - NCT07395739RecruitingPhase 1
Safety and immune response test of a new meningitis B vaccine
This trial tests a new vaccine called DX-104 to see if it is safe and helps the body fight meningitis B. Healthy adults aged 18-50 can join to help find a better way to prevent this infection.
Perth, Western AustraliaAges 18–50 - NCT07543380RecruitingPhase 3
RSV vaccine safety and immune response in high-risk adults
This study tests a new RSV vaccine designed to protect adults with chronic health conditions from severe RSV disease (a respiratory infection). Researchers will monitor how safe the vaccine is and how well your immune system responds to it.
Tsuchiura, IbarakiAges 18–59 - NCT07197762RecruitingPhase 4
Meningitis B Booster Shot Study for Young Adults
This trial tests two different booster shots for meningitis B in young adults who already got the Bexsero vaccine at least 2.5 years ago. The goal is to see which booster works best to keep you protected.
Atlanta, GeorgiaAges 18–25 - NCT07565740RecruitingPhase 1
Vaccine plus immunotherapy for newly diagnosed HPV-positive throat cancer
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
Chengdu, SichuanAges 18 years+ - NCT07112144RecruitingPhase 3
DTaP vaccine trial for healthy infants aged 2 months
This trial tests a new vaccine that protects against diphtheria, tetanus, and pertussis (whooping cough). It is for healthy infants who are about 2 months old and live permanently in the area. The goal is to see if the vaccine is safe and works well.
Wenshan Zhuang and Miao Autonomous Prefecture, YunnanAges 2 months–3 months
Hear when a new Vaccination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for vaccination?
- Yes. Clin2 currently lists 600 recruiting vaccination studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a vaccination trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a vaccination trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.